Home
|
Inbox
|
Search
|
Speaker
Steven W. Yancey
MBA, MS
GlaxoSmithKline;GSK
Session(s)
- Durability of Clinical Response Following Long-Term Treatment with Mepolizumab in Patients...
Sunday, May 20 11:15 AM - 1:00 PM - Effect of Mepolizumab (100 mg Subcutaneous) on Exacerbation Rate in Patients with Severe E...
Sunday, May 20 11:15 AM - 1:00 PM - Long-Term Safety of Mepolizumab in Patients with Severe Eosinophilic Asthma: The COLUMBA S...
Sunday, May 20 11:15 AM - 1:00 PM - Pharmacodynamic and Clinical Efficacy Data from Patient Sputum Subgroups in DREAM Treated ...
Sunday, May 20 11:15 AM - 1:00 PM - Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Respons...
Monday, May 21 11:15 AM - 1:00 PM - Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis...
Monday, May 21 2:15 PM - 4:15 PM - Fractional Exhaled Nitric Oxide and the Peripheral Blood Eosinophil Count as Biomarkers of...
Tuesday, May 22 2:15 PM - 4:15 PM - Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis...
Tuesday, May 22 3:30 PM - 3:45 PM
|
Home
|
Inbox
|
Search
|